Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant luteinising hormone in hypogonadotropic hypogonadal men
2024-518159-52-02Phase 3Completed
- Sponsor
- Department of Biomedical, Metabolic and Neural Sciences
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lutropin alfa in hypogonadotropic hypogonadism (HH), sponsored by Department of Biomedical, Metabolic and Neural Sciences. Primary endpoint: Total testosterone serum levels. Started Jan 2025; status: completed.
02
Drugs
lutropin alfa
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on 2024-518159-52-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518159-52-02.